Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Won Kim, MD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Phone415-353-7171
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      The Cooper Union for the Advancement of Science and ArtMDEngineering2003
      Weill Cornell Medicine CollegeMDMedicine2007

      Collapse ORNG Applications 
      Collapse Clinical Trials
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Kim W, Ryan CJ. Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. J Comp Eff Res. 2016 Jan; 5(1):5-7. PMID: 26690748.
        View in: PubMed
      2. Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll PR, Kim W, Ruggero D. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal. 2015; 8(403):ra116. PMID: 26577921.
        View in: PubMed
      3. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. PMID: 25336698; PMCID: PMC4277885 [Available on 12/15/15].
      4. Kim W, Ryan CJ. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer. 2015 Feb 1; 121(3):361-71. PMID: 25236176.
        View in: PubMed
      5. Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):292-9. PMID: 25047002.
        View in: PubMed
      6. Kim W, Ryan CJ. Friend or foe: the bifunctional role of steroid hormones in prostate cancer. Oncology (Williston Park). 2014 May; 28(5):408, 410. PMID: 25004655.
        View in: PubMed
      7. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):23-7. PMID: 24366412; PMCID: PMC4364998.
      8. Kim W, Febbo PG. . The current and future role of sequenced-based analysis in prostate cancer tretament. Personalized Medicine. 2013; 10(3):257-273.
      9. Kim W, Febbo PG. . RNA transcription and translation. In Stadler WM ed. Cancer Biology Review: A Case-Based Approach. 2013.
      10. Kim W, Ryan CJ. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol. 2012 Jun; 13(2):189-200. PMID: 22539224.
        View in: PubMed
      11. Gelbman BD, Cham MD, Kim W, Libby DM, Smith JP, Port JL, Altorki NK, Henschke CI, Yankelevitz DF. Radiographic and clinical characterization of false negative results from CT-guided needle biopsies of lung nodules. J Thorac Oncol. 2012 May; 7(5):815-20. PMID: 22729035.
        View in: PubMed
      Won's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP